1. NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC). (March 2019) Authors: Litton, J.; Symmans, F.; Gogineni, K.; Saltzman, M.; Telli, M.L.; Usha, L.; Chakrabarti, J.; Tudor, I.C.; Quek, R.G.W.; Czibere, A. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patient-reported outcomes (PROs) of cemiplimab (CEMI) versus platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: A focus on EMPOWER-Lung 1 (NCT03088540) age subgroups. (October 2022) Authors: Gogishvili, M.; Kilickap, S.; Sezer, A.; Gümüş, M.; Bondarenko, I.; Özgüroğlu, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R.G.W. Journal: Journal of geriatric oncology Issue: Volume 13(2022)Supplement 1 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. (November 2018) Authors: Hurvitz, S.A.; Quek, R.G.W.; Turner, N.C.; Telli, M.L.; Rugo, H.S.; Mailliez, A.; Ettl, J.; Grischke, E.; Mina, L.A.; Balmaña, J.; Fasching, P.A.; Bhattacharyya, H.; Hannah, A.L.; Robson, M.E.; Wardley, A.M. Journal: European journal of cancer Issue: Volume 104(2018) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗